United States Cardiovascular Disease Drugs Market Report & Forecast 2021-2027
Table of Contents1 Introduction to Research & Analysis Reports
1.1 Cardiovascular Disease Drugs Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 United States Cardiovascular Disease Drugs Market Overview
1.4 Methodology & Sources of Information
1.4.1 Research Methodology
1.4.2 Research Process
1.4.3 Base Year
2 United States Cardiovascular Disease Drugs Overall Market Size
2.1 United States Cardiovascular Disease Drugs Market Size: 2021 VS 2027
2.2 United States Cardiovascular Disease Drugs Revenue, Prospects & Forecasts: 2016-2027
2.3 United States Cardiovascular Disease Drugs Sales: 2016-2027
3 Company Landscape
3.1 Top Cardiovascular Disease Drugs Players in United States Market
3.2 Top United States Cardiovascular Disease Drugs Companies Ranked by Revenue
3.3 United States Cardiovascular Disease Drugs Revenue by Companies
3.4 United States Cardiovascular Disease Drugs Sales by Companies
3.5 United States Cardiovascular Disease Drugs Price by Manufacturer (2016-2021)
3.6 Top 3 and Top 5 Cardiovascular Disease Drugs Companies in United States Market, by Revenue in 2020
3.7 Manufacturers Cardiovascular Disease Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Cardiovascular Disease Drugs Players in United States Market
3.8.1 List of Tier 1 Cardiovascular Disease Drugs Companies in United States
3.8.2 List of Tier 2 and Tier 3 Cardiovascular Disease Drugs Companies in United States
4 Sights by Type
4.1 Overview
4.1.1 By Type - United States Cardiovascular Disease Drugs Market Size Markets, 2021 & 2027
4.1.2 Heparin
4.1.3 Coumadin
4.1.4 Sectral
4.1.5 Zebeta
4.1.6 Lopressor
4.1.7 Toprol XL
4.1.8 Norvasc
4.1.9 Lotrel
4.1.10 Others
4.2 By Type - United States Cardiovascular Disease Drugs Revenue & Forecasts
4.2.1 By Type - United States Cardiovascular Disease Drugs Revenue, 2016-2021
4.2.2 By Type - United States Cardiovascular Disease Drugs Revenue, 2022-2027
4.2.3 By Type - United States Cardiovascular Disease Drugs Revenue Market Share, 2016-2027
4.3 By Type - United States Cardiovascular Disease Drugs Sales & Forecasts
4.3.1 By Type - United States Cardiovascular Disease Drugs Sales, 2016-2021
4.3.2 By Type - United States Cardiovascular Disease Drugs Sales, 2022-2027
4.3.3 By Type - United States Cardiovascular Disease Drugs Sales Market Share, 2016-2027
4.4 By Type - United States Cardiovascular Disease Drugs Price (Manufacturers Selling Prices), 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - United States Cardiovascular Disease Drugs Market Size, 2021 & 2027
5.1.2 Asischemic Heart Disease
5.1.3 Dyslipidemia
5.1.4 Stroke
5.1.5 Thrombosis
5.1.6 Atherosclerosis
5.1.7 Coronary Artery Diseases
5.1.8 Peripheral Artery Disease
5.1.9 Others
5.2 By Application - United States Cardiovascular Disease Drugs Revenue & Forecasts
5.2.1 By Application - United States Cardiovascular Disease Drugs Revenue, 2016-2021
5.2.2 By Application - United States Cardiovascular Disease Drugs Revenue, 2022-2027
5.2.3 By Application - United States Cardiovascular Disease Drugs Revenue Market Share, 2016-2027
5.3 By Application - United States Cardiovascular Disease Drugs Sales & Forecasts
5.3.1 By Application - United States Cardiovascular Disease Drugs Sales, 2016-2021
5.3.2 By Application - United States Cardiovascular Disease Drugs Sales, 2022-2027
5.3.3 By Application - United States Cardiovascular Disease Drugs Sales Market Share, 2016-2027
5.4 By Application - United States Cardiovascular Disease Drugs Price (Manufacturers Selling Prices), 2016-2027
6 Manufacturers & Brands Profiles
6.1 AstraZeneca
6.1.1 AstraZeneca Corporation Information
6.1.2 AstraZeneca Overview
6.1.3 AstraZeneca Cardiovascular Disease Drugs Sales and Revenue in United States Market (2016-2021)
6.1.4 AstraZeneca Cardiovascular Disease Drugs Product Description
6.1.5 AstraZeneca Recent Developments
6.2 Johnson & Johnson
6.2.1 Johnson & Johnson Corporation Information
6.2.2 Johnson & Johnson Overview
6.2.3 Johnson & Johnson Cardiovascular Disease Drugs Sales and Revenue in United States Market (2016-2021)
6.2.4 Johnson & Johnson Cardiovascular Disease Drugs Product Description
6.2.5 Johnson & Johnson Recent Developments
6.3 Pfizer
6.3.1 Pfizer Corporation Information
6.3.2 Pfizer Overview
6.3.3 Pfizer Cardiovascular Disease Drugs Sales and Revenue in United States Market (2016-2021)
6.3.4 Pfizer Cardiovascular Disease Drugs Product Description
6.3.5 Pfizer Recent Developments
6.4 Sanofi
6.4.1 Sanofi Corporation Information
6.4.2 Sanofi Overview
6.4.3 Sanofi Cardiovascular Disease Drugs Sales and Revenue in United States Market (2016-2021)
6.4.4 Sanofi Cardiovascular Disease Drugs Product Description
6.4.5 Sanofi Recent Developments
6.5 Merck
6.5.1 Merck Corporation Information
6.5.2 Merck Overview
6.5.3 Merck Cardiovascular Disease Drugs Sales and Revenue in United States Market (2016-2021)
6.5.4 Merck Cardiovascular Disease Drugs Product Description
6.5.5 Merck Recent Developments
6.6 Daiichi Sankyo Company Limited
6.6.1 Daiichi Sankyo Company Limited Corporation Information
6.6.2 Daiichi Sankyo Company Limited Overview
6.6.3 Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Sales and Revenue in United States Market (2016-2021)
6.6.4 Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Product Description
6.6.5 Daiichi Sankyo Company Limited Recent Developments
6.7 Novartis
6.7.1 Novartis Corporation Information
6.7.2 Novartis Overview
6.7.3 Novartis Cardiovascular Disease Drugs Sales and Revenue in United States Market (2016-2021)
6.7.4 Novartis Cardiovascular Disease Drugs Product Description
6.7.5 Novartis Recent Developments
6.8 Bayer
6.8.1 Bayer Corporation Information
6.8.2 Bayer Overview
6.8.3 Bayer Cardiovascular Disease Drugs Sales and Revenue in United States Market (2016-2021)
6.8.4 Bayer Cardiovascular Disease Drugs Product Description
6.8.5 Bayer Recent Developments
6.9 Takeda Pharmaceutical
6.9.1 Takeda Pharmaceutical Corporation Information
6.9.2 Takeda Pharmaceutical Overview
6.9.3 Takeda Pharmaceutical Cardiovascular Disease Drugs Sales and Revenue in United States Market (2016-2021)
6.9.4 Takeda Pharmaceutical Cardiovascular Disease Drugs Product Description
6.9.5 Takeda Pharmaceutical Recent Developments
6.10 Roche
6.10.1 Roche Corporation Information
6.10.2 Roche Overview
6.10.3 Roche Cardiovascular Disease Drugs Sales and Revenue in United States Market (2016-2021)
6.10.4 Roche Cardiovascular Disease Drugs Product Description
6.10.5 Roche Recent Developments
6.11 United Therapeutics Corporation
6.11.1 United Therapeutics Corporation Corporation Information
6.11.2 United Therapeutics Corporation Overview
6.11.3 United Therapeutics Corporation Cardiovascular Disease Drugs Sales and Revenue in United States Market (2016-2021)
6.11.4 United Therapeutics Corporation Cardiovascular Disease Drugs Product Description
6.11.5 United Therapeutics Corporation Recent Developments
6.12 Actelion Pharmaceuticals
6.12.1 Actelion Pharmaceuticals Corporation Information
6.12.2 Actelion Pharmaceuticals Overview
6.12.3 Actelion Pharmaceuticals Cardiovascular Disease Drugs Sales and Revenue in United States Market (2016-2021)
6.12.4 Actelion Pharmaceuticals Cardiovascular Disease Drugs Product Description
6.12.5 Actelion Pharmaceuticals Recent Developments
6.13 Boehringer Ingelheim
6.13.1 Boehringer Ingelheim Corporation Information
6.13.2 Boehringer Ingelheim Overview
6.13.3 Boehringer Ingelheim Cardiovascular Disease Drugs Sales and Revenue in United States Market (2016-2021)
6.13.4 Boehringer Ingelheim Cardiovascular Disease Drugs Product Description
6.13.5 Boehringer Ingelheim Recent Developments
6.14 Astellas Pharma
6.14.1 Astellas Pharma Corporation Information
6.14.2 Astellas Pharma Overview
6.14.3 Astellas Pharma Cardiovascular Disease Drugs Sales and Revenue in United States Market (2016-2021)
6.14.4 Astellas Pharma Cardiovascular Disease Drugs Product Description
6.14.5 Astellas Pharma Recent Developments
7 United States Cardiovascular Disease Drugs Production Capacity, Analysis
7.1 United States Cardiovascular Disease Drugs Production Capacity, 2016-2027
7.2 Cardiovascular Disease Drugs Production Capacity of Key Manufacturers in United States Market
8 Key Market Trends, Opportunity, Drivers and Restraints
8.1 Market Opportunities & Trends
8.2 Market Drivers
8.3 Market Restraints
9 Cardiovascular Disease Drugs Supply Chain Analysis
9.1 Cardiovascular Disease Drugs Industry Value Chain
9.2 Cardiovascular Disease Drugs Upstream Market
9.3 Cardiovascular Disease Drugs Downstream and Clients
9.4 Marketing Channels Analysis
9.4.1 Marketing Channels
9.4.2 Cardiovascular Disease Drugs Distributors and Sales Agents in United States Market
10 Conclusion
11 Appendix
11.1 Note
11.2 Examples of Clients
11.3 Author Details
11.4 Disclaimer
List of TablesTable 1. Key Players of Cardiovascular Disease Drugs in United States Market
Table 2. Top Cardiovascular Disease Drugs Players in United States Market, Ranking by Revenue (2019)
Table 3. United States Cardiovascular Disease Drugs Revenue by Companies, (US$, Mn), 2016-2021
Table 4. United States Cardiovascular Disease Drugs Revenue Share by Companies, 2016-2021
Table 5. United States Cardiovascular Disease Drugs Sales by Companies, (K Units), 2016-2021
Table 6. United States Cardiovascular Disease Drugs Sales Share by Companies, 2016-2021
Table 7. Key Manufacturers Cardiovascular Disease Drugs Price (2016-2021) & (USD/Units)
Table 8. Manufacturers Cardiovascular Disease Drugs Product Type
Table 9. List of Tier 1 Cardiovascular Disease Drugs Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Tier 2 and Tier 3 Cardiovascular Disease Drugs Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. Major Manufacturers of Heparin
Table 12. Major Manufacturers of Coumadin
Table 13. By Type - United States Cardiovascular Disease Drugs Revenue, (US$, Mn), 2021 & 2027
Table 14. By Type - United States Cardiovascular Disease Drugs Revenue (US$, Mn), 2016-2021
Table 15. By Type - United States Cardiovascular Disease Drugs Revenue (US$, Mn), 2022-2027
Table 16. By Type - United States Cardiovascular Disease Drugs Sales (K Units), 2016-2021
Table 17. By Type - United States Cardiovascular Disease Drugs Sales (K Units), 2022-2027
Table 18. By Application - United States Cardiovascular Disease Drugs Revenue, (US$, Mn), 2021 VS 2027
Table 19. By Application - United States Cardiovascular Disease Drugs Revenue (US$, Mn), 2016-2021
Table 20. By Application - United States Cardiovascular Disease Drugs Revenue (US$, Mn), 2022-2027
Table 21. By Application - United States Cardiovascular Disease Drugs Sales (K Units), 2016-2021
Table 22. By Application - United States Cardiovascular Disease Drugs Sales (K Units), 2022-2027
Table 23. AstraZeneca Corporation Information
Table 24. AstraZeneca Description and Major Businesses
Table 25. AstraZeneca Cardiovascular Disease Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Units) (2016-2021)
Table 26. AstraZeneca Cardiovascular Disease Drugs Product
Table 27. AstraZeneca Recent Developments
Table 28. Johnson & Johnson Corporation Information
Table 29. Johnson & Johnson Description and Major Businesses
Table 30. Johnson & Johnson Cardiovascular Disease Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Units) (2016-2021)
Table 31. Johnson & Johnson Cardiovascular Disease Drugs Product
Table 32. Johnson & Johnson Recent Developments
Table 33. Pfizer Corporation Information
Table 34. Pfizer Description and Major Businesses
Table 35. Pfizer Cardiovascular Disease Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Units) (2016-2021)
Table 36. Pfizer Cardiovascular Disease Drugs Product
Table 37. Pfizer Recent Developments
Table 38. Sanofi Corporation Information
Table 39. Sanofi Description and Major Businesses
Table 40. Sanofi Cardiovascular Disease Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Units) (2016-2021)
Table 41. Sanofi Cardiovascular Disease Drugs Product
Table 42. Sanofi Recent Developments
Table 43. Merck Corporation Information
Table 44. Merck Description and Major Businesses
Table 45. Merck Cardiovascular Disease Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Units) (2016-2021)
Table 46. Merck Cardiovascular Disease Drugs Product
Table 47. Merck Recent Developments
Table 48. Daiichi Sankyo Company Limited Corporation Information
Table 49. Daiichi Sankyo Company Limited Description and Major Businesses
Table 50. Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Units) (2016-2021)
Table 51. Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Product
Table 52. Daiichi Sankyo Company Limited Recent Developments
Table 53. Novartis Corporation Information
Table 54. Novartis Description and Major Businesses
Table 55. Novartis Cardiovascular Disease Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Units) (2016-2021)
Table 56. Novartis Cardiovascular Disease Drugs Product
Table 57. Novartis Recent Developments
Table 58. Bayer Corporation Information
Table 59. Bayer Description and Major Businesses
Table 60. Bayer Cardiovascular Disease Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Units) (2016-2021)
Table 61. Bayer Cardiovascular Disease Drugs Product
Table 62. Bayer Recent Developments
Table 63. Takeda Pharmaceutical Corporation Information
Table 64. Takeda Pharmaceutical Description and Major Businesses
Table 65. Takeda Pharmaceutical Cardiovascular Disease Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Units) (2016-2021)
Table 66. Takeda Pharmaceutical Cardiovascular Disease Drugs Product
Table 67. Takeda Pharmaceutical Recent Developments
Table 68. Roche Corporation Information
Table 69. Roche Description and Major Businesses
Table 70. Roche Cardiovascular Disease Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Units) (2016-2021)
Table 71. Roche Cardiovascular Disease Drugs Product
Table 72. Roche Recent Developments
Table 73. United Therapeutics Corporation Corporation Information
Table 74. United Therapeutics Corporation Description and Major Businesses
Table 75. United Therapeutics Corporation Cardiovascular Disease Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Units) (2016-2021)
Table 76. United Therapeutics Corporation Cardiovascular Disease Drugs Product
Table 77. United Therapeutics Corporation Recent Developments
Table 78. Actelion Pharmaceuticals Corporation Information
Table 79. Actelion Pharmaceuticals Description and Major Businesses
Table 80. Actelion Pharmaceuticals Cardiovascular Disease Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Units) (2016-2021)
Table 81. Actelion Pharmaceuticals Cardiovascular Disease Drugs Product
Table 82. Actelion Pharmaceuticals Recent Developments
Table 83. Boehringer Ingelheim Corporation Information
Table 84. Boehringer Ingelheim Description and Major Businesses
Table 85. Boehringer Ingelheim Cardiovascular Disease Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Units) (2016-2021)
Table 86. Boehringer Ingelheim Cardiovascular Disease Drugs Product
Table 87. Boehringer Ingelheim Recent Developments
Table 88. Astellas Pharma Corporation Information
Table 89. Astellas Pharma Description and Major Businesses
Table 90. Astellas Pharma Cardiovascular Disease Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Units) (2016-2021)
Table 91. Astellas Pharma Cardiovascular Disease Drugs Product
Table 92. Astellas Pharma Recent Developments
Table 93. Cardiovascular Disease Drugs Production Capacity (K Units) of Key Manufacturers in United States Market, 2019-2021 (K Units)
Table 94. United States Cardiovascular Disease Drugs Capacity Market Share of Key Manufacturers, 2019-2021
Table 95. Cardiovascular Disease Drugs Market Opportunities & Trends in United States Market
Table 96. Cardiovascular Disease Drugs Market Drivers in United States Market
Table 97. Cardiovascular Disease Drugs Market Restraints in United States Market
Table 98. Cardiovascular Disease Drugs Raw Materials
Table 99. Cardiovascular Disease Drugs Raw Materials Suppliers in United States Market
Table 100. Typical Cardiovascular Disease Drugs Downstream
Table 101. Cardiovascular Disease Drugs Downstream Clients in United States Market
Table 102. Cardiovascular Disease Drugs Distributors and Sales Agents in United States Market
List of FiguresFigure 1. Cardiovascular Disease Drugs Product Picture
Figure 2. Cardiovascular Disease Drugs Segment by Type
Figure 3. Cardiovascular Disease Drugs Segment by Application
Figure 4. United States Cardiovascular Disease Drugs Market Overview: 2020
Figure 5. United States Cardiovascular Disease Drugs Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. United States Cardiovascular Disease Drugs Revenue, 2016-2027 (US$, Mn)
Figure 7. Cardiovascular Disease Drugs Sales in United States Market: 2016-2027 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Cardiovascular Disease Drugs Revenue in 2020
Figure 9. Heparin Product Picture
Figure 10. Coumadin Product Picture
Figure 11. Sectral Product Picture
Figure 12. Zebeta Product Picture
Figure 13. Lopressor Product Picture
Figure 14. By Type - United States Cardiovascular Disease Drugs Sales Market Share, 2016-2027
Figure 15. By Type - United States Cardiovascular Disease Drugs Revenue Market Share, 2016-2027
Figure 16. By Type - United States Cardiovascular Disease Drugs Price (USD/Units), 2016-2027
Figure 17. Asischemic Heart Disease
Figure 18. Dyslipidemia
Figure 19. Stroke
Figure 20. Thrombosis
Figure 21. Atherosclerosis
Figure 22. By Application - United States Cardiovascular Disease Drugs Sales Market Share, 2016-2027
Figure 23. By Application - United States Cardiovascular Disease Drugs Revenue Market Share, 2016-2027
Figure 24. By Application - United States Cardiovascular Disease Drugs Price (USD/Units), 2016-2027
Figure 25. AstraZeneca Cardiovascular Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 26. Johnson & Johnson Cardiovascular Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 27. Pfizer Cardiovascular Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 28. Sanofi Cardiovascular Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 29. Merck Cardiovascular Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 30. Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 31. Novartis Cardiovascular Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 32. Bayer Cardiovascular Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 33. Takeda Pharmaceutical Cardiovascular Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 34. Roche Cardiovascular Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 35. United Therapeutics Corporation Cardiovascular Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 36. Actelion Pharmaceuticals Cardiovascular Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 37. Boehringer Ingelheim Cardiovascular Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 38. Astellas Pharma Cardiovascular Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 39. United States Cardiovascular Disease Drugs Production Capacity (K Units), 2016-2027
Figure 40. Cardiovascular Disease Drugs Industry Value Chain
Figure 41. Marketing Channels